At Clyne Health, your satisfaction and well-being are our top priorities. Whether you have questions about our products, need support with an order, or just want to learn more, we’re here to assist you every step of the way.
Shop by
At Clyne Health, your satisfaction and well-being are our top priorities. Whether you have questions about our products, need support with an order, or just want to learn more, we’re here to assist you every step of the way.
Clyne.Health provides access to GLP-1 treatments, including Mounjaro® (tirzepatide), Wegovy® (semaglutide), Ozempic® (semaglutide), and Zepbound™ (tirzepatide), through licensed U.S. pharmacies. Compounded versions of semaglutide and tirzepatide are not approved or evaluated for safety, efficacy, or quality by the FDA. Ozempic® is FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a provider’s discretion. Wegovy® and Zepbound™ are FDA-approved for chronic weight management. Mounjaro® is FDA-approved for type 2 diabetes treatment and may be prescribed off-label for weight management.
All prescription products require an online evaluation with an independent licensed medical professional who determines if treatment is appropriate. Medications are prescribed by independent licensed physicians as part of Clyne programs. Actual product packaging may differ from images shown. Physicians may prescribe compounded medications only when clinically necessary to meet patient needs or during FDA-recognized drug shortages.
By requesting prescription items, you consent to Clyne.Health facilitating access to an independent licensed provider for evaluation. If approved, prescriptions may be filled at one of our partner pharmacies unless you choose an alternative. Clyne.Health may also use de-identified data for marketing purposes, including targeted advertising on platforms such as Google and Meta. You may opt out of marketing emails anytime by following the unsubscribe instructions in each message or by contacting us at help@clyne.health.
